ScholarIQanswers from OpenAlex & ORCID
Donna Niedzwiecki
ResearcherPublications, citations & collaboration network
Donna Niedzwiecki is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Donna Niedzwiecki have?
ScholarIQindexed works
Donna Niedzwiecki has 622 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Donna Niedzwiecki have?
ScholarIQcitation count
Donna Niedzwiecki has 30,243 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Donna Niedzwiecki?
ScholarIQh-index
Donna Niedzwiecki has an h-index of 87 in OpenAlex.
What is the i10-index of Donna Niedzwiecki?
ScholarIQi10-index
Donna Niedzwiecki has an i10-index of 281 in OpenAlex.
What is the ORCID of Donna Niedzwiecki?
ScholarIQorcid
The ORCID for Donna Niedzwiecki is on the source record.
What is the OpenAlex record for Donna Niedzwiecki?
ScholarIQopenalex
The OpenAlex for Donna Niedzwiecki is on the source record.
What are the most-cited papers on Donna Niedzwiecki?
ScholarIQmost cited works
Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781
Joel E. Tepper, Mark J. Krasna, Donna Niedzwiecki, Donna Hollis, Carolyn E. Reed, Richard M. Goldberg, Krystyna Kiel, Christopher G. Willett, David J. Sugarbaker, Robert J. Mayer
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
Axel Grothey, Alberto Sobrero, Anthony F. Shields, Takayuki Yoshino, James Paul, Julien Taı̈eb, John Souglakos, Qian Shi, Rachel Kerr, Roberto Labianca, Jeffrey A. Meyerhardt, Déwi Vernerey, Takeharu Yamanaka, Ioannis Boukovinas, Jeffrey P. Meyers, Lindsay A. Renfro, Donna Niedzwiecki, Toshiaki Watanabe, Valter Torri, Mark Saunders, Daniel J. Sargent, Thierry André, Timothy Iveson
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer
Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz, Federico Innocenti, Briant Fruth, Jeffrey A. Meyerhardt, Deborah Schrag, Claire Greene, Bert H. O’Neil, James N. Atkins, Scott Berry, Blasé N. Polite, Eileen M. O’Reilly, Richard M. Goldberg, Howard S. Höchster, Richard L. Schilsky, Monica M. Bertagnolli, Anthony B. El-Khoueiry, Peter J. Watson, Al B. Benson, Daniel Mulkerin, Robert J. Mayer, Charles D. Blanke
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy L. Kindler, Donna Niedzwiecki, Donna Hollis, Susan Sutherland, Deborah Schrag, Herbert I. Hurwitz, Federico Innocenti, Mary F. Mulcahy, Eileen M. O’Reilly, Timothy F. Wozniak, Joel Picus, Pankaj Bhargava, Robert J. Mayer, Richard L. Schilsky, Richard M. Goldberg
Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803
Jeffrey A. Meyerhardt, Denise Heseltine, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, James P. Thomas, Heidi Nelson, Renaud Whittom, Alexander Hantel, Richard L. Schilsky, Charles S. Fuchs